ArticleAnnals of surgical oncology2026
Correlation of Serum DR-70 Levels with Pathological Stage and Nuclear Grade in Localized Renal Cell Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReliable biomarkers for predicting tumor aggressiveness and pathological upstaging in renal cell carcinoma (RCC) remain limited. DR-70, a biomarker reflecting circulating fibrin and fibrin degradation products, has been associated with tumor progression in several malignancies. This study aimed to investigate the association between preoperative serum DR-70 levels and pathological stage and nuclear grade in patients with localized RCC.
methodsThis prospective single-center study included 69 patients who underwent partial or radical nephrectomy for localized RCC. Tumors were staged according to the TNM classification and graded using the World Health Organization/International Society of Urological Pathology system. Preoperative serum DR-70 levels were measured, and their associations with clinical stage, pathological stage, and nuclear grade were evaluated. Multivariate logistic regression analysis was performed to identify independent predictors of pathological upstaging (≥ pT3). Receiver operating characteristic curve analysis was used to assess the predictive performance of DR-70.
resultsThe median serum DR-70 level was 0.84 U/mL. DR-70 levels were significantly higher in high-grade tumors than in low-grade tumors (1.32 vs. 0.78 U/mL, p = 0.001). No significant association was observed between DR-70 levels and clinical stage (p = 0.53), whereas a significant association was found with pathological stage (p = 0.023). Multivariate analysis identified serum DR-70 as an independent predictor of pathological upstaging (≥ pT3) (odds ratio 1.40; 95% confidence interval 1.09-1.81; p = 0.008). Receiver operating characteristic analysis demonstrated good predictive performance for high-grade disease (area under the curve 0.823) and pathological upstaging (area under the curve 0.774), with an optimal cutoff value of 1.02 U/mL.
conclusionsSerum DR-70 was associated with tumor aggressiveness and independently predicted pathological upstaging in patients with localized RCC. These findings suggest that DR-70 may serve as a complementary biomarker for preoperative risk stratification and may help identify patients at increased risk of aggressive pathological features. Larger multicenter studies are warranted to validate these findings.
Indexed as
Identifiers
42860498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.